Expert Reviews Potential Novel Treatment Options in Ovarian Cancer

Video

Ritu Salani, MD, highlights the possible benefit of a novel targeted therapy and autologous tumor vaccine in patients with platinum-resistant ovarian cancer, and in the maintenance setting after treatment for platinum-sensitive disease.

Following the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Ritu Salani, MD, discussed two potential treatments for patients with platinum-resistant ovarian cancer, including targeted agent upifitamab rilsodotin (XMT-1536) and autologous tumor vaccine gemogenovatucel-T (Virgil), that warrant future research.

Salani, the Gynecologic Oncology Fellowship Director at University of California Los Angeles Health and the Gynecologic Oncology editorial board member for the journal ONCOLOGY®, highlighted upifitamab rilsodotin’s capability of targeting NaPi2b, a target commonly expressed in platinum-resistant ovarian cancer. According to Salani, upifitamab rilsodotin may also benefit patients as maintenance therapy following treatment for platinum-sensitive disease.

Salani also spoke about gemogenovatucel-T, which she described as being a potential maintenance therapy option for patients with homologous repair proficient (HRP) disease that may not require PARP inhibitors as supplemental treatment.

Transcript:

For ovarian cancer, we continue to have struggles in the platinum-resistance setting. Mirvetuximab soravtansine-gynx (Elahere) is going to help advance that field. But there are other targets that are being explored. This includes things like upifitamab rilsodotin, which is an antibody-drug conjugate targeting NaPi2b. [For] patients who have high expression of this target, which is not uncommon in ovarian cancer—even probably around the 50% range—there's a targeted agent. This might also provide another avenue of treatment both in the platinum-resistance setting and as a maintenance option after platinum-sensitive treatment.

The other ideas that are kind of out there are looking at HRP maintenance in patients without using a PARP inhibitor. We know PARP inhibitors have some benefit, but it has not been that ‘wow factor’ that we're all looking for. [Gemogenovatucel-T], which is looking at the patient's own tumor and looking at reinfusing it [via] an agent [as part of a] maintenance strategy, is something that's out there. And this is really exciting. In preliminary data, it looks like the patients with HRP [disease] have the best benefit. We're looking forward to getting more information about that.

Related Videos
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.
Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Adverse effects associated with oral azacitidine in low- or intermediate-risk MDS are typically transient, according to Mikkael A. Sekeres, MD, MS.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Ongoing genomic profiling analyses in the ASC4FIRST trial may further determine which patients with CML may benefit from treatment with asciminib.
Related Content